Drugs / Enlonstobart
Trials 25 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03852823 | May 2019 → Sep 2022 | cervical cancer, lymphoma, malignant mesothelioma, non-small cell lung carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07622225 | May 2026 → Dec 2028 expected | neoplasm | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07282509 | Dec 2025 → Jun 2028 expected | hepatocellular carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07288814 | Dec 2025 → Dec 2026 expected | peripheral T-cell lymphoma, not otherwise specified | Sun Yat-sen University Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06132217 | Jan 2024 → Jan 2027 expected | neoplasm | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06136988 | Dec 2023 → Apr 2027 expected | esophageal squamous cell carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05508659 | Sep 2022 → Sep 2024 | cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07448077 | Mar 2026 overdue | — | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07281157 | Nov 2025 → Apr 2027 expected | rectal cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06989671 | Aug 2025 → Dec 2027 expected | head and neck squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06998771 | Jun 2025 → Jun 2028 expected | carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06981858 | May 2025 → Feb 2029 expected | cervical carcinoma | Chongqing University Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07183865 | Mar 2025 → Mar 2030 expected | rectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06089330 | Jan → Jul 2024 | colorectal cancer | Shanghai JMT-Bio Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05068141 | Oct 2021 → Oct 2022 | triple-negative breast carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05009953 | Sep 2021 → Jan 2023 | gallbladder carcinoma, intrahepatic cholangiocarcinoma | CSPC Ouyi Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT04983550 | Sep 2021 → Jan 2023 | fallopian tube cancer, malignant epithelial tumor of ovary, peritoneum cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04886700 | Jul 2021 → Dec 2022 | cervical cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT07662811 | Jun 2026 → Dec 2027 expected | non-small cell lung carcinoma | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07585279 | May 2026 → Feb 2031 expected | colorectal cancer | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07332533 | Dec 2025 → Jun 2032 expected | carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07251062 | Dec 2025 → Dec 2029 expected | esophageal squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07672223 | Jun 2026 → Sep 2029 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07633873 | Jun 2026 → Sep 2027 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05715840 | Jan 2023 → Jul 2024 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06682611 Comparator | Nov 2024 → Nov 2026 expected | — | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07714668 Comparator | Aug 2026 → Apr 2028 expected | ovarian cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07254585 Background | Dec 2025 → Jun 2026 overdue | head and neck squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enlonstobart | “Enlonstobart (SG001) is a fully humanized and high-affinity anti-PD-1 immunoglobulin G4 monoclonal antibody.” PMID 39447517 ↗ Oct 202414“Enlonstobart Enlonstobart 200mg IV every 3 weeks” NCT07448077 ↗ “Enlonstobart: 240mg, ivgtt, d1” NCT07281157 ↗ |
| Known as | SG001 | “Enlonstobart (SG001) is a fully humanized and high-affinity anti-PD-1 immunoglobulin G4 monoclonal antibody.” PMID 39447517 ↗ Oct 2024 |
| Known as | SG001: Enlonstobart | “SG001: Enlonstobart” NCT07251062 ↗ |
| Action | Inhibit | “novel PD-1 inhibitor” PMID 39447517 ↗ Oct 2024 |
| Modality | Monoclonal antibody | “SG001 is a humanized, IgG4 monoclonal antibody against human PD-1.” PMID 41321671 ↗ Nov 2025 |
| Route | Intravenous | “Subjects will receive intravenous infusion of SG001” NCT03852823 ↗ |
| Target | PDCD1 | “SG001 is a humanized, IgG4 monoclonal antibody against human PD-1.” PMID 41321671 ↗ Nov 2025 |